GLP-1 Intestine and Stomach Paralysis Complications A recent case report published in January 2024 discussed Semaglutides (the active ingredient in Ozempic, Wegovy, and Rybelsus) known gastrointestinal adverse effects, and highlighted the need [for medical providers] to recognize medication-induced gastroparesis as a possible diagnosis, especially in individuals with risk factors. The weight loss and diabetes drug lawyers here at Mazie Slater are investigating claims of serious side effects and complications in people who utilized certain glucagon-like peptide 1 (GLP-1) receptor agonist (RA) medications for diabetes and weight loss
What began as a gastroenterological curiosity became, over 25 years, an evergreen of regenerative research
The FDA regulates products based on risk and therapeutic claims, not the molecule itself
GLP-1 agonists are not new to the pharmaceutical landscape
This allowed us to gauge the product's efficacy, taste, mixability, and any potential side effects
.jpg?w=8688&max-h=5792&fit=crop&auto=format)
